Τόμος 10 (1996) – Τεύχος 1 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 10 (1996) – Issue 1 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

3^rd Department of Neurology, Aristotle University of Thessaloniki, General Hospital G. Papanicolaou, Exohi, Thessaloniki, Macedonia, Greece

4.     Snyder S.H., Reynolds I.J.: Calcium-antagonist drugs. Receptor interactions that clarify therapeutic effects. N. Engl. J. Med 313: 995-1002 (1985)

5.     Reichle M.E.: The pathophysiology of brain ischaemia. Ann. Neurol. 13: 2-10 (1983)

6.     Yamomoto M., Ohta T., Toda N.: Mechanisms of relaxant action of nicardipine, a new Ca⁺⁺ antagonist, on isolated dog cerebral and mesenteric arteries. Stroke 14: 270-275 (1983)

7.     Grotta J.C.: Current medical and surgical therapy for cerebrovascular disease. N. Engl. J. Med. 377: 1506-1517 (1987)

8.     Ban T.A., Morey L., Aguglia E., Azzareili O., Balsano F., Marigliano V., Caglieris N., Sterlicchio M., Capurso A., Tomasi N.A. et al.: Nimodipine in the treatment of old age dementias. Prog. Neuropsychopharmacol. Biol. Psychiatry 14: 525-551 (1990)

9.     Centonze V., Massaro C., Polito B.M., Cassiano M.A., Di Bari M., Russo P., Cirillo L., Albano O.: Brain aging and calcium antagonist drugs. A preliminary open study with nimodipine. Clin. Ter. 140: 11-15 (1992)

10.    Steen P.A., Newberg I.A., Milde J.H., Michenfeider J.D.: Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischaemia in the dog. J. Cereb. Blood Flow Metab. 3: 38-43 (1983)

11.    Wahlgren N.G.: Acute stroke therapy – Calcium blockers. 2^nd International Conference on Stroke, Geneva, Switzerland 1993

12.    Goldstein M., Lew J.Y., Hata F., Lieberman A.: Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology (Suppl 1): 24:76 (1978)

13.    Suchy I.H.: Clinical effects of dopamine agonists in elderly patients. In: Lisuride and other Dopamine Agonists (D.B. Caine et al., eds), p. 529, Raven Press, New York

14.    Lucchelli A., Zonta F., Grana E., Turba C., Pagella P.: Dualism in the alpha-adrenoreceptor blocking action of dihydroergocristine. Pharmacol. Res. Comm. 13: 23 (1981)

15.    Morpurgo C., Faini D., Falcone A.: Effects of phentolamine, dihydroergocristine and isoxuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats. Naunyn. Schmiedeberg’s Arch. Pharmacol. 290: 335 (1975)

16.    Grana E., D’ Agostino G., Zonta F., Lucchelli A.: Actions and interactions of ergotamine and dihydroergocristine in rat aortic strips. Farmaco, Ed. Sei. 8: 109 (1981)

17.    D’ Urso R., Falaschi P., Jeccamo R., Ruggieri S.: Effect of dihydroergocristine on prolactin release from isolated and dispersed rat pituitary cells. Acta Ther. 8: 109 (1982)

18.    Poli M., Bonetti M., Bosi E.: Effeto inhibitorio della diidroergicristina sulla secrezione di prolattina indotta da sulpiride e da cimetidina nell’ uomo. J. Endocrinol. Invest. 3 (Suppl 1): 32 (1980)

19.    Gamba G., Grignani G., Dolci D.: Effeto in vivo della diidroergocristina sulla funzione di piastrine umane. Arch. Set. Med. 135: 249 (1978)

20.    Benzi G., Arrigoni E., Pastoris O., Raimondo S., Dossena M., Fulle D., Tumminello M.C., Villa R.F.: Drug interference on some biochemical parameters of rat cerebral cortex during post-ischemic recovery. Arch. Int. Pharmacodyn. Ther. 247: 198 (1980)

21.    Venutti P., Ferretti C., Portaleone P.: Ergot alkaloids and phosphodiesterase in vitro activities, in several rat brain areas. Experientia 38: 601 (1982)

22.    Kohlmeyer K., Blessing J.: Zur Wirkung von Dihydroergocristine-methansulfonat auf den Hirnkreislauf des Menschen in Akutversuch. Unteruchungen mit der intrakaritidialen ¹³³Xenon-clearance-Method. Arzneim.- Forsch. 28: 1788 (1978)

23.    Agnoli A., Manna V., Bocola V., Martucci N.: Chronic cerebro-vascular disorders: Modifications of the EEG spectral analysis determined by dihydroergocristine methanesulfonate. Curr. Ther. Res. 20: 321 (1981)

24.    Martucci N., Manna V., Prencipe M., Agnoli A.: Validation of pharmaco-EEG and neuropsychology as experimental methods in clinical neuropharmacology. In: Cerebral pathology in Old Age. Neuroradiological and Neurophysiological Correlations (A. Cecchni et al., eds), p. 373, EMI RAS, Pavia, 1983

25.    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3^rd Edition revised, pp. 97-134, DSM IHR, 1987

26.    Report of the NINCDS-ADRDA Work Group: Clinical diagnosis of Alzheimer’s disease. Neurology 34: 939- 944 (1984)

27.    Folstein M.F., Folstein S.E., McHugh P.R.: MMSE: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189-198 (1975)

28.    Fountoulakis K., Tsolaki M., Chantzi E., Kazis A.: Mini Mental State Examination. Validation Study in Demented Patients from the elderly Greek Population. 9^th Greek Conference for Neurosciences, Book of Abstract 36, Thessaloniki, 1993

29.    Roth M., Huppert F.A., Tym E., Mountjoy C.Q.: CAMDEX. Cambridge University Press, 1988

30.    Hachinski V.V., Iliff L.D., Zihkla E et al.: Cerebral blood flow in dementia. Arch. Neurol. 32: 632-637 (1975)

31.    Hutton J.T.: Alzheimer’s Disease. In: Conn’s Current Therapy. 778-781 (1990)

32.    Hamilton M.: A Rating Scale for depression. J. Neurol. Neurosurg. Psychlatr.: 23-56 (1960)

33.    Sheikh J.I., Yesavage J.A.: Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clin. Gerontologist 5: 165-173 (1986)

34.    Crook T.H., Bartus R.T., Ferris S.H., Whitehouse P., Cohen G.D., Gershon S.: Age associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of the National Institute of Mental Health Workgroup. Develop. Neuropsychol. 2: 261-276 (1986)

35.    Sclar D.A., Skaer T.L.: Current concepts in the treatment of Alzheimer’s disease. Clin. Ther. 14: 2-10 (1992)

36.    Cooper J.K.: Drug treatment of Alzheimer’s disease. Arch. Int. Med. 151: 245-249 (1991)

37.    Tedeschi D.: Calcium regulation in brain aging by nimodipine: a multicenter trial in Italy. Curr. Ther. Res. 50: 553-563 (1991)

38.    Ulrich G., Stieglitz R.D.: Effect of nimodipine upon EEG Vigilance in elderly persons with minor impairment of brain functions. Arzneim. -Forsch. 3: 392-396 (1988)

39.    Ban T.A., Morey L., Aguglia E., et al.: Nimodipine in the treatment of old age dementias. Prog. Neuropsychopharmacol. Biol. Psychiatry 74: 525-551 (1990)

40.    Tollefson G.D.: Short term effects of the calcium channel blocker nimodipine in the management of primary degenerative dementia. Biol. Psychiatry 27: 1133-1142 (1990)

41.    Weiss J.H., Pike C.J., Cotman C.W.: Ca²⁺ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J. Neurochem. 62: 372-375 (1994)

42.    Branconnier R.J., Branconnier M.E., Walshe T.M., McCarthy C.: Blocking the Ca²⁺-activated cytotoxic mechanisms of cholinergic neuronal death. Psychopharmacol. Bull. 28: 175-181 (1992)

43.    Hulla F.W.: Presentation of data from European nimodipine studies. Sixth Congress of the International Psychogeriatric Association, Berlin, 1993

44.    Schmage N., Bergener M.: Global rating, symptoms, behavior and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes. Int. Psychogeriatr. Suppl 1: 89-99 (1992)

45.    Reimann I.: Alzheimer’s disease. Starting points in drug therapy. Dtsch. Apoth. Ztg.: 959-969 (1990)

46.    Jann M.W., Miller S.W., Miyahara R., et al.: A controlled clinical trial of nimodipine in the treatment of patients with Primary Degenerative Dementia (PDD). Pharmacotherapy 12: 507 (1992)

47.    Branconnier R.J., Harto N.E., Dessain E.C., Cole J.O.: Palliation of the progressive memory impairment of Alzheimer’s disease by nimodipine. Psychopharmacology 96 (Suppl.): 242 (1988)

48.    Dessain E.C., McNiff M.E., Spera K.F., Branconnier RJ.: Nimodipine induced normalization of the EEG in Primary Degenerative Dementia. Acta Pharmacol. Toxicol. 59 (Suppl, 5): 104 (1986)

49.    Grobe-Einsler R.: Clinical aspects of nimodipine, Clin. Neuropharmacol. 16 (Suppl. 1): S39-S45 (1993)

50.    Hilgert D., Eicher H., Liebl D., et al.: Nimodipine therapy of multimorbid geriatric patients with organic psychosyndrome: Pharmacodynamics and Pharmacokinetics. Med. Welt 43(1): 20-26 (1992)

51.    Imperato A., Obinu M.C., Dazzi L, Carata G., Mascia M.S., Casu M.A., Gessa G.L.: Co-dergocrine (Hydergine) regulates striatal and hippocampal acetylcholine release through D2 receptors. Neuroreport 5: 674-676 (1994)

52.    Favit A., Sortino M.A., Aleppo G., Scapagnini U., Canonico P.L.: Protection by dihydroergocryptine of glutamate-induced neurotoxicity. Pharmacol. Toxicol. 73: 224-228 (1993)

53.    Abate G., Angelert F., Bartorelli L, Batistin L, Bergamasco B., Bertolini S., Bulfoni A., Capurso A., Cazzato G., Covvagna G., et al.: Epidemiologic study on the effectiveness and safety of dihydroergocrystine in impaired memory and behavioral functions in aged humans. Arzneim.-Forschung 42: 1417-1421 (1992)

54.  Agliati G., Lazzaroni M., Mariani G., Marras F., Masseto N., Menozzi C., Ortenzi E., Perna G., Puppo N., Santambrogio S., et al.: One year therapy with dihydergocrystine for treatment of impaired alertness and memory in elderly patients. Placebo-controlled multicenter study. Arzneim.-Forschung 42: 1414-1416 (1992)